at higher doses, because of chromosomal damage (Boue and Boue, 1973; Laufer et al., 1982) or an anti-oestrogen effect David N.Curole 1,2,3 , Phillip H.Rye 1,2,3 , Peter Y.Lu 1,2, and Roman Pyrzak 1,2 on the endometrium (Dickey et al., 1993a), has also been suggested. (Quigley et al., 1984; Shalev et al., 1989) . Information about the relationship between clomiphene dose and multiple births 4 To whom correspondence should be addressed at: Fertility Institute is limited to four studies (Corson et al., 1983; Hammond and of New Orleans, 6020 Bullard Avenue, New Orleans, LA 70128, USA Talbert, 1983; Groll, 1984; Dickey et al., 1992). Recently, we reported an inverse relationship between clomiphene citrate Our objective was to examine the relationship between dose and preclinical abortion, with no relationship between patient weight and the dose of clomiphene required for clomiphene dose and clinical abortion or multiple pregnancy, pregnancy so as to assess the validity of recommendations in a retrospective analysis of 1738 clomiphene citrate-induced that the dose of clomiphene be limited to 100 mg. We pregnancies (Dickey et al., 1996). retrospectively analysed the weight-dose relationship in
. Recently, we reported an inverse relationship between clomiphene citrate Our objective was to examine the relationship between dose and preclinical abortion, with no relationship between patient weight and the dose of clomiphene required for clomiphene dose and clinical abortion or multiple pregnancy, pregnancy so as to assess the validity of recommendations in a retrospective analysis of 1738 clomiphene citrate-induced that the dose of clomiphene be limited to 100 mg. We pregnancies (Dickey et al., 1996) .
retrospectively analysed the weight-dose relationship in
The objective of this study was to investigate the need for 1681 clomiphene pregnancies and the relationship between clomiphene citrate doses Ͼ100 mg/day by analysing the dose and pregnancy, births, multiple births, number of relationship between maternal weight at conception and clomipre-ovulatory follicles and endometrial thickness in 2841 phene citrate dose, and that between clomiphene dose and cycles of clomiphene treatment, 25-250 mg, for 5 days the number of pre-ovulatory follicles, endometrial thickness, before intrauterine insemination (IUI). Doses of clomiphene pregnancy, births and multiple births in cycles of intrauterine Ͼ100 mg/day were used before pregnancies in 27.4% of insemination (IUI). patients who weighed Ͼ90 kg and in 14.7% of all pregnancies. In IUI cycles, pregnancies and births, but not multiple births or abortions, were related to dose. An increase in Materials and methods dose from 25 to 100 mg resulted in higher pregnancy and birth rates, and in an increase in the average number of (FDA) has been limited to 100 mg/day for 5 days. Many patients require higher doses to achieve ovulation and pregnancy (Rust Ovulation induction protocol et al., 1974; Gorlitsky et al., 1978; Gysler et al., 1982; Lobo Clomiphene citrate was administered for 5 days, at an initial dose of et al., 1982) . Shepard et al. (1979) and Lobo et al. (1982) 25 mg/day for patients who weighed Ͻ45 kg, 50 mg/day for those have related the need for higher doses to body weight. However, who weighed 45-68 kg and 100 mg/day for those who weighed Ͼ68 the largest of these studies comprised Ͻ200 pregnancies.
kg. The dose of clomiphene citrate was increased by 25-50 mg in Reasons given for limiting the dose of clomiphene citrate each subsequent cycle until a satisfactory ovarian response was are concerns about hyperstimulation, ovarian cysts and multiple evident by both biphasic basal body temperature chart and a midluteal phase serum progesterone concentration ജ2000 ng/dl. The dose pregnancy. The possibility of an increased incidence of abortion of clomiphene was decreased if symptoms of hot flushes or scintillating scotoma occurred.
Insemination
Ovulation was timed by the urine LH surge using OvuStick (Quidel Inc., San Diego, CA, USA) or Q Test (Becton-Dickenson, Sparks, MD, USA), beginning on cycle day 10. When HCG (10 000 IU) was used to facilitate IUI timing, it was given when one or more follicles was ജ18 mm in diameter. A single IUI was performed 34-36 h after HCG administration or between 18 and 24 h after the detection of an LH surge. A urine pregnancy test was performed 14 days after insemination. Information about semen quality, ovulation induction medication, diagnosis, age and previous pregnancy outcome were entered into a computer database at the time of insemination.
Ultrasound
Follicular development was assessed by a transvaginal ultrasound performed 5 days after the last dose of clomiphene citrate using an ATL Ultramark 4 DP ultrasound (Advanced Technology Laboratories Inc., Bothell, WA, USA) and a 5.0 MHz transducer. If no follicles were found to be ജ18 mm in diameter, but some were ജ13 mm in diameter, patients were instructed to administer HCG 1 or 2 days later if a spontaneous urine LH surge did not occur first. If follicles were Ͻ13 mm in diameter, patients were instructed to return in 3 days for a repeat ultrasound. Wall to wall endometrial thickness was measured at the time of ultrasound for follicular size from 1991 onwards, as described previously (Dickey et al., 1993b) .
Pregnancy test and follow-up
All pregnancies from IUI or other treatments, including pregnancies without ovulation induction, were confirmed by serum quantitative β-HCG measurements. Pregnancies were entered into a pregnancy computer database at the time the pregnancy was confirmed, in addition to information about patient weight, age, previous pregnancy, diagnoses and treatment. All newly pregnant patients were routinely Figure 1 . Relationship between clomiphene dose and: (A) mean scanned by ultrasound at between 4.5 and 5.5 weeks of gestation to maternal weight at the time of conception and (B) Ponderal index (height in inches/cube root of weight in pounds); (n) measured; confirm the presence of an intrauterine gestation and to determine (m) calculated (n ϭ 1681). Pearson's correlation coefficient: weight the number of gestational sacs. An ultrasound was repeated 14 days r ϭ 0.22, P Ͻ 0.001; Ponderal index r ϭ 0.16, P Ͻ 0.001. later to confirm fetal viability. Pregnancies were followed until 12-16 weeks of gestation, before referral for the continuation of prenatal care and delivery. Vital statistics of the birth were either self-reported (Ponderal index r ϭ -0.16; P Ͻ 0.001). The correlation by the patient or obtained from her delivery physician. between dose and obesity was not stronger than the correlation with weight alone (Figure 1 ). Doses of clomiphene citrate Analysis Ͼ100 mg/day were used by 14.7% of all pregnant patients
The relationship of clomiphene citrate dose to maternal weight at and by 27.4% of patients who weighed Ͼ90 kg (Table I) .
conception is reported in kilograms (kg) and pounds (lb), and as the There was considerable overlap. Doses Ͼ100 mg/day were Ponderal obesity index (height in inches, divided by the cube root of used by 6.8% of patients who weighed Ͻ45 kg, while 24.5% weight in pounds). Results of IUI are reported as pregnancy, including of patients who weighed ജ90 kg became pregnant with doses preclinical abortions, clinical abortions and ectopic pregnancies, and of 50 mg/day. Clomiphene citrate (25 mg) was used by 9.1% birth rates per cycle. Statistical analyses were performed using Fisher's exact test and Pearson's correlation coefficient. Results were of patients who weighed Ͻ45 kg and by 3.3% of all patients, considered to be significant at P Ͻ 0.05. but by none who weighed Ͼ74 kg.
Relationship between clomiphene dose and pregnancy, birth
Results and multiple birth in IUI cycles Relationship between clomiphene dose used at conception Clomiphene doses from 25 to 250 mg were used in 2841 and patient weight cycles of IUI in which spermatozoa met the minimal standards needed for pregnancy. The dose of clomiphene citrate was The weight and height of each patient were recorded at conception in 6117 pregnancies, including 1681 of the 1738 correlated with pregnancy (r ϭ 0.05; P ϭ 0.004) and birth (r ϭ 0.04; P ϭ 0.011) rates, but not with multiple birth rates clomiphene citrate-induced pregnancies. The clomiphene dose taken during the cycle of conception was significantly correl- (Table II) . Pregnancy and birth rates averaged 8.7 and 5.8% respectively for clomiphene citrate doses of 25-50 mg, comated with patient weight (r ϭ 0.22; P Ͻ 0.001) and obesity pared with 11.7 and 7.8% for doses of 75-200 mg; these rates Discussion were significantly different between doses (P ϭ 0.002 and The findings of our study confirm and extend those of others P Ͻ 0.022 respectively).
who found a linear relationship between maternal weight and the clomiphene citrate dose needed for pregnancy. The large Relationship between clomiphene dose, the number of prenumber of clomiphene citrate-induced pregnancies in our study ovulatory follicles and endometrial thickness (1681), compared with the 47 pregnancies and 117 patients The number of pre-ovulatory follicles and endometrial thicktreated by Shepard et al. (1979) and the 158 patients treated ness were determined in 1487 cycles in which ultrasound was by Lobo et al. (1982) , allow us to define more precisely the performed on the day of the LH surge or HCG administration.
relationship between patient weight and the need for higher Increases in clomiphene dose, from 25 to 100 mg, were related clomiphene citrate doses than was possible with smaller to small but significant increases in the number of pre-ovulatory numbers of patients. Most importantly, we found that doses follicles (Table III and Figure 2) . Doses of clomiphene citrate Ͼ100 mg/day were employed in the cycle of pregnancy by Ͼ100 mg/day did not result in any further increase in the 27.4% of patients who weighed ജ90 kg and by 14.7% of numbers of follicles. patients overall. We found considerable overlap, as did previous Endometrial thickness was measured on the day of the LH authors. A dose of 50 mg/day was sufficient for 24.5% of surge or HCG administration in 577 cycles. Endometrial patients who weighed ജ90 kg. On the other end of the weight thickness, determined on the day of HCG administration, was scale, 3.3% of patients overall and 9.1% of patients who not related to clomiphene citrate dose (Table IV) .
weighed Ͻ45 kg became pregnant on a dose of 25 mg/day. The clomiphene dose was minimally related to the day of Our findings are intermediate between those of Gorlitsky IUI in 3127 cycles, which included cycles without ultrasound et al. (1978) , who noted that 5.6% of their total pregnancies measurements and with poor semen quality. The day of IUI occurred at doses Ͼ100 mg/day, and Rust et al. (1974) , who advanced from 12.8 days for a dose of 25 mg to 13.3 days reported that 22.5% of their total pregnancies occurred at doses of 150-250 mg daily, or Gysler et al. (1982) , who found for a dose ജ150 mg (Table IV) . Mean ( Correlation: clomiphene dose with number of follicles: ജ12 mm r ϭ 0.13, P Ͻ 0.001; ജ15 mm r ϭ 0.10, P Ͻ 0.001; ജ18 mm r ϭ 0.05, P Ͻ 0.03; ജ21 mm r ϭ 0.03, P non-significant. Correlation: clomiphene dose with: thickness, r ϭ 0.04, not significant; cycle day of insemination, r ϭ 0.09, P Ͻ 0.001.
These authors reported a linear correlation (r ϭ 0.46) between dose and maternal weight in 56 patients who ovulated, and speculated that a closer relationship might have been obtained if dose was compared with an obesity index. They also found that oestrone concentrations were higher in obese women, and suggested that, because of this, higher doses of clomiphene citrate were required to compete with endogenous oestrogen for hypothalamic receptor sites. Lobo et al. (1982) confirmed a correlation between dose and maternal weight (r ϭ 0.93), and also a correlation between dose and the ponderal obesity index (r ϭ 0.93), in 51 patients who ovulated. In addition, they attempted to define the relationship between endogenous hormones and clomiphene citrate response. They found that serum LH, total testosterone and dehydroepiandrosterone sulphate concentrations were higher, but that serum-unbound oestradiol concentrations were no different in women who ovulated compared with those who failed to ovulate. Crosignani et al. (1994) found that women in the upper tertiles of body weight measured as the ponderal index who received 225 IU/ fewer oocytes retrieved than women who weighed less. In our study, the correlation between dose and maternal weight (r ϭ that 26.7% of pregnancies occurred at clomiphene citrate doses 0.22) and between dose and the ponderal index (r ϭ -0.16) ജ150 mg/day, and Shepard et al. (1979) , who found that during the cycle of conception was not as strong as the 28.0% of pregnancies occurred at doses ജ150 mg/day. relationship reported by the previous authors. Of those who investigated the relationship between clomi-
The finding that doses of ജ100 mg/day are associated with phene citrate dose and pregnancy, only Shepard et al. (1979) higher per cycle pregnancy and birth rates than doses of 25-50 mg/day, with no increase in the number of abortions or compared the relationship between dose and patient weight. mm in diameter (Dickey et al., 1992) . In the present study, found that while clomiphene citrate increased progesterone concentrations in patients with luteal insufficiency, the progesterone concentrations attained were not dose related. The evidence in our study, that doses of clomiphene citrate Ͼ100 mg/day increase per cycle birth rates and do not cause a significant increase in the number of pre-ovulatory follicles, multiple births or abortions, strongly supports the use of clomiphene citrate doses higher than the 100 mg/day limit presently imposed by the United States FDA, especially for women with excessive weight. There remain many reasons why pregnancies may fail to occur in ovulation induction cycles; having an insufficiently high dose of clomiphene citrate should not be one of them.
